Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 10 de 10
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Exp Dermatol ; 33(3): e15040, 2024 Mar.
Article de Anglais | MEDLINE | ID: mdl-38429888

RÉSUMÉ

The effect of persistent skin inflammation on extracutaneous organs and blood is not well studied. Patients with recessive dystrophic epidermolysis bullosa (RDEB), a severe form of the inherited blistering skin disorder, have widespread and persistent skin ulcers, and they develop various complications including anaemia, hyperglobulinaemia, hypoalbuminaemia and secondary amyloidosis. These complications are associated with the bioactivities of IL-6, and the development of secondary amyloidosis requires the persistent elevation of serum amyloid A (SAA) level. We found that patients with RDEB had significantly higher serum levels of IL-6 and SAA compared to healthy volunteers and patients with psoriasis or atopic dermatitis. Both IL-6 and SAA were highly expressed in epidermal keratinocytes and dermal fibroblasts of the skin ulcer lesions. Keratinocytes and fibroblasts surrounding the ulcer lesions are continuously exposed to Toll-like receptor (TLR) ligands, pathogen-associated and damage-associated molecular pattern molecules. In vitro, TLR ligands induced IL-6 expression via NF-κB in normal human epidermal keratinocytes (NHEKs) and dermal fibroblasts (NHDFs). SAA further induced the expression of IL-6 via TLR1/2 and NF-κB in NHEKs and NHDFs. The limitation of this study is that NHEKs and NHDFs were not derived from RDEB patients. These observations suggest that TLR-mediated persistent skin inflammation might increase the risk of IL-6-related systemic complications, including RDEB.


Sujet(s)
Amyloïdose , Épidermolyse bulleuse dystrophique , Interleukine-6 , Humains , Amyloïdose/métabolisme , Amyloïdose/anatomopathologie , Collagène de type VII/métabolisme , Épidermolyse bulleuse dystrophique/métabolisme , Épidermolyse bulleuse dystrophique/anatomopathologie , Fibroblastes/métabolisme , Inflammation/métabolisme , Interleukine-6/métabolisme , Kératinocytes/métabolisme , Facteur de transcription NF-kappa B/métabolisme , Protéine amyloïde A sérique/métabolisme , Récepteurs de type Toll/métabolisme
6.
Int J Mol Sci ; 22(23)2021 Nov 23.
Article de Anglais | MEDLINE | ID: mdl-34884474

RÉSUMÉ

Interleukin (IL) 23 (p19/p40) plays a critical role in the pathogenesis of psoriasis and is upregulated in psoriasis skin lesions. In clinical practice, anti-IL-23Ap19 antibodies are highly effective against psoriasis. IL-39 (p19/ Epstein-Barr virus-induced (EBI) 3), a newly discovered cytokine in 2015, shares the p19 subunit with IL-23. Anti-IL-23Ap19 antibodies may bind to IL-39; also, the cytokine may contribute to the pathogenesis of psoriasis. To investigate IL23Ap19- and/or EBI3-including cytokines in psoriatic keratinocytes, we analyzed IL-23Ap19 and EBI3 expressions in psoriasis skin lesions, using immunohistochemistry and normal human epidermal keratinocytes (NHEKs) stimulated with inflammatory cytokines, using quantitative real-time polymerase chain reaction (RT-PCR), enzyme-linked immunosorbent assay (ELISA), and liquid chromatography-electrospray tandem mass spectrometry (LC-Ms/Ms). Immunohistochemical analysis showed that IL-23Ap19 and EBI3 expressions were upregulated in the psoriasis skin lesions. In vitro, these expressions were synergistically induced by the triple combination of tumor necrosis factor (TNF)-α, IL-17A, and interferon (IFN)-γ, and suppressed by dexamethasone, vitamin D3, and acitretin. In ELISA and LC-Ms/Ms analyses, keratinocyte-derived IL-23Ap19 and EBI3, but not heterodimeric forms, were detected with humanized anti-IL-23Ap19 monoclonal antibodies, tildrakizumab, and anti-EBI3 antibodies, respectively. Psoriatic keratinocytes may express IL-23Ap19 and EBI3 proteins in a monomer or homopolymer, such as homodimer or homotrimer.


Sujet(s)
Sous-unité p19 de l'interleukine-23/métabolisme , Interleukines/métabolisme , Antigènes mineurs d'histocompatibilité/métabolisme , Psoriasis/immunologie , Régulation positive , Anticorps monoclonaux humanisés/pharmacologie , Lignée cellulaire , Chromatographie en phase liquide , Cytokines/génétique , Cytokines/métabolisme , Humains , Sous-unité p19 de l'interleukine-23/génétique , Interleukines/génétique , Kératinocytes/immunologie , Antigènes mineurs d'histocompatibilité/génétique , Psoriasis/génétique , Spectrométrie de masse ESI , Spectrométrie de masse en tandem , Régulation positive/effets des médicaments et des substances chimiques
7.
J Dermatol ; 48(4): 547-550, 2021 Apr.
Article de Anglais | MEDLINE | ID: mdl-33410193

RÉSUMÉ

Toxic shock syndrome (TSS) is caused by toxic shock syndrome toxin 1 or enterotoxins secreted by Staphylococcus aureus. Lipopolysaccharide (LPS) has also been shown to play a major role in the development of sepsis. Staphylococcal superantigens and LPS operate synergistically in conditioning cytokine release and lethal shock in mice. An 80-year-old woman was admitted because of a 20% mixed-depth flame burn. Despite two excisions and grafts, necrotic ulcers with methicillin-resistant Staphylococcus aureus (MRSA) colonization remained. On the 7th day after the operation, she developed shock with an erythematous rash. Blood examination revealed evidence of disseminated intravascular coagulation, and liver and renal dysfunction. A blood culture revealed a staphylococcal enterotoxin B (SEB)-producing strain of MRSA and Klebsiella pneumoniae. The septic symptoms were prolonged, but the condition gradually improved with extensive treatment. T-cell receptor analysis demonstrated a marked accumulation of SEB-mediated Vß T cells. Stimulation of peripheral blood mononuclear cells in the recovery phase with SEB and LPS induced additive effects on tumor necrosis factor-α, interferon-γ, and interleukin-6 production. Although the present case did not fulfill the clinical criteria for TSS, the additive effects of SEB and LPS might have caused the severe septic shock.


Sujet(s)
Brûlures , Staphylococcus aureus résistant à la méticilline , Choc septique , Infections à staphylocoques , Animaux , Brûlures/complications , Entérotoxines , Humains , Agranulocytes , Lipopolysaccharides , Souris , Choc septique/étiologie , Infections à staphylocoques/complications , Superantigènes
8.
Int J Mol Sci ; 21(3)2020 Jan 30.
Article de Anglais | MEDLINE | ID: mdl-32019242

RÉSUMÉ

The serine proteases kallikrein-related peptidase (KLK) 5 and KLK7 cleave cell adhesion molecules in the epidermis. Aberrant epidermal serine protease activity is thought to play an important role in the pathogenesis of atopic dermatitis (AD). We collected the stratum corneum (SC) from healthy individuals (n = 46) and AD patients (n = 63) by tape stripping and then measuring the trypsin- and chymotrypsin-like serine protease activity. We also analyzed the p.D386N and p.E420K of SPINK5 variants and loss-of-function mutations of FLG in the AD patients. The serine protease activity in the SC was increased not only in AD lesions but also in non-lesions of AD patients. We found, generally, that there was a positive correlation between the serine protease activity in the SC and the total serum immunoglobulin E (IgE) levels, serum thymus and activation-regulated chemokine (TARC) levels, and peripheral blood eosinophil counts. Moreover, the p.D386N or p.E420K in SPINK5 and FLG mutations were not significantly associated with the SC's serine protease activity. Epidermal serine protease activity was increased even in non-lesions of AD patients. Such activity was found to correlate with a number of biomarkers of AD. Further investigations of serine proteases might provide new treatments and prophylaxis for AD.


Sujet(s)
Marqueurs biologiques/analyse , Eczéma atopique/enzymologie , Épiderme/enzymologie , Protéases à sérine/métabolisme , Adulte , Marqueurs biologiques/métabolisme , Études cas-témoins , Eczéma atopique/anatomopathologie , Femelle , Protéines filaggrine , Humains , Mâle , Mutation , Protéines S100/génétique , Protéines S100/métabolisme , Inhibiteur de sérine peptidase de type Kazal-5/génétique , Inhibiteur de sérine peptidase de type Kazal-5/métabolisme
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE